

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

Test Report Status **Final**

Results

Biological Reference Interval Units

HAEMATOLOGY - CBC

COMPLETE CARE TOTAL WITH SMART REPORT

BLOOD COUNTS, EDTA WHOLE BLOOD

| | | | |
|---|-------------------|-------------|---------------|
| HEMOGLOBIN (HB) | 14.5 | 13.0 - 17.0 | g/dL |
| METHOD : CYANMETHEMOGLOBIN METHOD | | | |
| RED BLOOD CELL (RBC) COUNT | 5.01 | 4.5 - 5.5 | mil/ μ L |
| METHOD : ELECTRICAL IMPEDANCE | | | |
| WHITE BLOOD CELL (WBC) COUNT | 14.10 High | 4.0 - 10.0 | thou/ μ L |
| METHOD : ELECTRICAL IMPEDANCE | | | |
| PLATELET COUNT | 296 | 150 - 410 | thou/ μ L |
| METHOD : ELECTRONIC IMPEDANCE/CALCULATION | | | |

RBC AND PLATELET INDICES

| | | | |
|--|------------------|-------------|------|
| HEMATOCRIT (PCV) | 43.9 | 40 - 50 | % |
| METHOD : ELECTRICAL IMPEDANCE | | | |
| MEAN CORPUSCULAR VOLUME (MCV) | 88.0 | 83 - 101 | fL |
| METHOD : CALCULATED PARAMETER | | | |
| MEAN CORPUSCULAR HEMOGLOBIN (MCH) | 28.9 | 27.0 - 32.0 | pg |
| METHOD : CALCULATED PARAMETER | | | |
| MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) | 32.9 | 31.5 - 34.5 | g/dL |
| METHOD : CALCULATED PARAMETER | | | |
| RED CELL DISTRIBUTION WIDTH (RDW) | 14.3 High | 11.6 - 14.0 | % |
| METHOD : CALCULATED PARAMETER | | | |
| MENTZER INDEX | 17.6 | | |
| MEAN PLATELET VOLUME (MPV) | 8.1 | 6.8 - 10.9 | fL |
| METHOD : CALCULATED PARAMETER | | | |

WBC DIFFERENTIAL COUNT

| | | | |
|-------------------------------|----|---------|---|
| NEUTROPHILS | 62 | 40 - 80 | % |
| METHOD : ELECTRICAL IMPEDANCE | | | |
| LYMPHOCYTES | 32 | 20 - 40 | % |
| METHOD : ELECTRICAL IMPEDANCE | | | |
| MONOCYTES | 4 | 2 - 10 | % |
| METHOD : ELECTRICAL IMPEDANCE | | | |
| EOSINOPHILS | 2 | 1 - 6 | % |
| METHOD : ELECTRICAL IMPEDANCE | | | |



Dr. Himani Sharma
Lab Head

Page 1 Of 16



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000005180288

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

| | | | |
|--|------------------|-------------|---------|
| BASOPHILS METHOD : ELECTRICAL IMPEDANCE | 0 | 0 - 2 | % |
| ABSOLUTE NEUTROPHIL COUNT | 8.74 High | 2.0 - 7.0 | thou/μL |
| ABSOLUTE LYMPHOCYTE COUNT | 4.51 High | 1.0 - 3.0 | thou/μL |
| ABSOLUTE MONOCYTE COUNT | 0.56 | 0.2 - 1.0 | thou/μL |
| ABSOLUTE EOSINOPHIL COUNT | 0.28 | 0.02 - 0.50 | thou/μL |
| ABSOLUTE BASOPHIL COUNT | 0.00 Low | 0.02 - 0.10 | thou/μL |
| NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD : CALCULATED | 1.5 | | |

PERIPHERAL SMEAR EXAM, EDTA WHOLE BLOOD

RBC RBC ARE PREDOMINANTLY NORMOCYTIC NORMOCHROMIC.
MILD ANISOPOIKILOCYTOSIS IS SEEN.
NO NUCLEATED RBC SEEN.POLYCHROMASIA IS NOT RAISED.

METHOD : MICROSCOPIC EXAMINATION

WBC TOTAL LEUCOCYTE COUNT IS RAISED.
DIFFERENTIAL COUNT SHOWS ABSOLUTE NEUTROPHILIA AND
ABSOLUTE LYMPHOCYTOSIS

METHOD : MICROSCOPIC EXAMINATION

PLATELETS PLATELETS ARE ADEQUATE IN NUMBER

METHOD : MICROSCOPIC EXAMINATION

IMPRESSION NORMOCYTIC NORMOCHROMIC SMEAR WITH LEUCOCYTOSIS
ABSOLUTE NEUTROPHILIA AND ABSOLUTE LYMPHOCYTOSIS.
KINDLY CORRELATE CLINICALLY.

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.
RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.
WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.
(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504
This ratio element is a calculated parameter and out of NABL scope.



Dr. Himani Sharma
Lab Head

Page 2 Of 16



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000005180288

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

Test Report Status **Final**

Results

Biological Reference Interval Units

HAEMATOLOGY

COMPLETE CARE TOTAL WITH SMART REPORT

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD


E.S.R 03 0 - 14 mm at 1 hr
METHOD : MODIFIED WESTERGREN

GLYCOSYLATED HEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD

HBA1C 5.7 Non-diabetic: < 5.7 %
Pre-diabetics: 5.7 - 6.4
Diabetics: > or = 6.5
Therapeutic goals: < 7.0
Action suggested : > 8.0
(ADA Guideline 2021)

METHOD : HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE (EAG) **116.9 High** < 116.0 mg/dL
METHOD : CALCULATED PARAMETER




Dr. Himani Sharma
Lab Head

Page 3 Of 16



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000005180288

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

Test Report Status **Final**

Results

Biological Reference Interval Units

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitis, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (**>100 mm/hour**) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr (62 if anemic) and in second trimester (0-70 mm/hr (95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs (Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

GLYCOSYLATED HEMOGLOBIN (HbA1C), EDTA WHOLE BLOOD-**Used For:**

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
2. Diagnosing diabetes.
3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.
2. eAG gives an evaluation of blood glucose levels for the last couple of months.
3. eAG is calculated as $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

HbA1c Estimation can get affected due to :

1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
2. Vitamin C & E are reported to falsely lower test results (possibly by inhibiting glycation of hemoglobin).
3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy



Dr. Himani Sharma
Lab Head



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote

Amritsar, 143001

Punjab, India

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000005180288

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

Test Report Status **Final**

Results

Biological Reference Interval Units


BIOCHEMISTRY

COMPLETE CARE TOTAL WITH SMART REPORT

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 86 Normal : < 100 mg/dL
Pre-diabetes: 100-125
Diabetes: >=126

METHOD : HEXOKINASE



LIVER FUNCTION PROFILE, SERUM

| | | | |
|--|------|-----------|-------|
| BILIRUBIN, TOTAL | 0.37 | 0.2 - 1.0 | mg/dL |
| METHOD : DIAZOTIZED SULFANILIC ACID / CAFFEINE | | | |
| BILIRUBIN, DIRECT | 0.08 | 0.0 - 0.2 | mg/dL |
| METHOD : DIAZO WITH SULPHANILIC ACID | | | |
| BILIRUBIN, INDIRECT | 0.29 | 0.1 - 1.0 | mg/dL |
| METHOD : CALCULATED PARAMETER | | | |
| TOTAL PROTEIN | 6.9 | 6.4 - 8.2 | g/dL |
| METHOD : BIURET | | | |
| ALBUMIN | 3.9 | 3.4 - 5.0 | g/dL |
| METHOD : BCG DYE BINDING METHOD | | | |



Dr. Himani Sharma
Lab Head

Page 5 Of 16



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000005180288

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
|--------------------|-------|---------|-------------------------------|-------|

| | | | |
|----------|-----|-----------|------|
| GLOBULIN | 3.0 | 2.0 - 4.1 | g/dL |
|----------|-----|-----------|------|

METHOD : CALCULATED PARAMETER

| | | | |
|------------------------|-----|-----------|-------|
| ALBUMIN/GLOBULIN RATIO | 1.3 | 1.0 - 2.1 | RATIO |
|------------------------|-----|-----------|-------|

METHOD : CALCULATED PARAMETER

| | | | |
|--------------------------------------|----|---------|-----|
| ASPARTATE AMINOTRANSFERASE(AST/SGOT) | 25 | 15 - 37 | U/L |
|--------------------------------------|----|---------|-----|

METHOD : ASPARTIC ACID, PYRIDOXAL 5 PHOSPHATE / UV

| | | | |
|-------------------------------------|----------------|--------|-----|
| ALANINE AMINOTRANSFERASE (ALT/SGPT) | 46 High | < 45.0 | U/L |
|-------------------------------------|----------------|--------|-----|

METHOD : ALANINE, PYRIDOXAL 5 PHOSPHATE / LDH

| | | | |
|----------------------|----|----------|-----|
| ALKALINE PHOSPHATASE | 82 | 30 - 120 | U/L |
|----------------------|----|----------|-----|

METHOD : PNPP - AMP BUFFER

| | | | |
|----------------------------------|----|---------|-----|
| GAMMA GLUTAMYL TRANSFERASE (GGT) | 28 | 15 - 85 | U/L |
|----------------------------------|----|---------|-----|

METHOD : GCNA

| | | | |
|-----------------------|-----|----------|-----|
| LACTATE DEHYDROGENASE | 161 | 85 - 227 | U/L |
|-----------------------|-----|----------|-----|

METHOD : L-LACTATE, NAD / UV

LIPID PROFILE WITH CALCULATED LDL

| | | | |
|--------------------|-----|--|-------|
| CHOLESTEROL, TOTAL | 189 | < 200 Desirable 200 - 239 Borderline High ≥ 240 High | mg/dL |
|--------------------|-----|--|-------|

METHOD : CHOLESTEROL ESTERASE (CE) / CHOLESTEROL OXIDASE (CO)

| | | | |
|---------------|-----------------|--|-------|
| TRIGLYCERIDES | 228 High | < 150 Normal 150 - 199 Borderline High 200 - 499 High ≥ 500 Very High | mg/dL |
|---------------|-----------------|--|-------|

METHOD : LIPOPROTEIN LIPASE (LPL), GLYCEROL KINASE (GK)

| | | | |
|-----------------|---------------|-----------------------|-------|
| HDL CHOLESTEROL | 36 Low | < 40 Low ≥ 60 High | mg/dL |
|-----------------|---------------|-----------------------|-------|

METHOD : PEG MODIFIED CHOLESTEROL ESTERASE AND CHOLESTEROL OXIDASE

| | | | |
|-----------------|-----------------|---|-------|
| CHOLESTEROL LDL | 107 High | < 100 Optimal 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High ≥ 190 Very High | mg/dL |
|-----------------|-----------------|---|-------|

METHOD : DIRECT HOMOGENOUS

| | | | |
|---------------------|-----------------|--|-------|
| NON HDL CHOLESTEROL | 153 High | Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220 | mg/dL |
|---------------------|-----------------|--|-------|



Dr. Himani Sharma
Lab Head

Page 6 Of 16



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

**Patient Ref. No. 775000005180288**

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

Test Report Status **Final**

Results

Biological Reference Interval Units

VERY LOW DENSITY LIPOPROTEIN

45.6 High

<= 30.0

mg/dL

METHOD : CALCULATED PARAMETER

CHOL/HDL RATIO

5.3 High

3.3 - 4.4
Low Risk
4.5 - 7.0
Average Risk
7.1 - 11.0
Moderate Risk
> 11.0
High Risk


METHOD : CALCULATED PARAMETER

LDL/HDL RATIO

3.0

0.5 - 3.0 Desirable/Low Risk
3.1 - 6.0 Borderline/Moderate Risk
>6.0 High Risk

METHOD : CALCULATED PARAMETER




Dr. Himani Sharma
Lab Head

Page 7 Of 16



View Details



View Report

PERFORMED AT :**Agilus Diagnostics Ltd.**

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

**Patient Ref. No. 775000005180288**

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : 0202WJ007460

PATIENT ID : PREEM19027978A

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 44 Years Male

DRAWN : 21/10/2023 12:36:27



RECEIVED : 21/10/2023 12:39:49

REPORTED : 21/10/2023 14:56:46

Test Report Status **Final**

Results

Biological Reference Interval Units

**KIDNEY FUNCTION TEST**


Dr. Himani Sharma
Lab Head

Page 8 Of 16



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000005180288

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

| Test Report Status | <u>Final</u> | Results | Biological Reference Interval | Units |
|---|--------------|---------|-------------------------------|--------|
| BLOOD UREA NITROGEN | | 12 | 6 - 20 | mg/dL |
| METHOD : UREASE -GLDH | | | | |
| CREATININE | | 1.06 | 0.90 - 1.30 | mg/dL |
| METHOD : PICRATE / NAOH / JAFFE | | | | |
| BUN/CREAT RATIO | | 11.32 | 5.00 - 15.00 | |
| METHOD : CALCULATED PARAMETER | | | | |
| URIC ACID | | 7.0 | 3.5 - 7.2 | mg/dL |
| METHOD : URICASE UV | | | | |
| TOTAL PROTEIN | | 6.9 | 6.4 - 8.2 | g/dL |
| METHOD : BIURET | | | | |
| ALBUMIN | | 3.9 | 3.4 - 5.0 | g/dL |
| METHOD : BCG DYE BINDING METHOD | | | | |
| GLOBULIN | | 3.0 | 2.0 - 4.1 | g/dL |
| METHOD : CALCULATED PARAMETER | | | | |
| CALCIUM | | 8.5 | 8.5 - 10.1 | mg/dL |
| METHOD : O-CRESOLPHTHALEIN COMPLEXONE | | | | |
| SODIUM, SERUM | | 139 | 136 - 145 | mmol/L |
| METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY | | | | |
| POTASSIUM, SERUM | | 4.04 | 3.50 - 5.10 | mmol/L |
| METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY | | | | |
| CHLORIDE, SERUM | | 103 | 98 - 107 | mmol/L |
| METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY | | | | |



Dr. Himani Sharma
Lab Head

Page 9 Of 16



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000005180288

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : 0202WJ007460

PATIENT ID : PREEM19027978A

CLIENT PATIENT ID:

ABHA NO :

AGE/SEX : 44 Years Male

DRAWN : 21/10/2023 12:36:27



RECEIVED : 21/10/2023 12:39:49

REPORTED : 21/10/2023 14:56:46

Test Report Status **Final**

Results

Biological Reference Interval Units



MAGNESIUM, SERUM



Dr. Himani Sharma
Lab Head

Page 10 Of 16



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote

Amritsar, 143001

Punjab, India

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000005180288

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID :
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

| Test Report Status | Final | Results | Biological Reference Interval | Units |
|--------------------|-------|---------|-------------------------------|-------|
| MAGNESIUM, SERUM | | 1.8 | 1.8 - 2.4 | mg/dL |

Interpretation(s)**GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in: Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), Drugs-insulin, ethanol, propranolol, sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease, Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

MAGNESIUM, SERUM-Description- Magnesium is primarily an intracellular ion associated with GI absorption and renal excretion. Second most abundant ion in bone. It functions as co-factor in numerous enzymes e.g. ATPase. 65-70% of Mg is in ionized state and nearly 35% is protein bound.

Interpretation-

Increased in- Dehydration, Tissue trauma, Renal failure, Hypothyroidism, excessive intake of antacid.

Decrease in- Chronic diarrhea, Enteric fistula, Starvation, Chronic alcoholism, Total parenteral Nutrition, Diuretics.

Note- Hypomagnesemia is associated with weakness, tetany, disorientation and somnolence

Limitation-

- Hemolysis yields elevated levels of Mg being an intracellular ion.
- Serum magnesium levels may remain normal even when total body stores of magnesium are depleted up to 20%



Dr. Himani Sharma
Lab Head

Page 11 Of 16



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000005180288

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

Test Report Status **Final**

Results

Biological Reference Interval Units

SPECIALISED CHEMISTRY - ANEMIA

COMPLETE CARE TOTAL WITH SMART REPORT

SERUM IRON AND TIBC STUDIES

| | | | |
|---|-----|-----------|-------|
| IRON | 73 | 65 - 175 | µg/dL |
| METHOD : CHROMOPHORE FERENE / ASCORBIC ACID | | | |
| TOTAL IRON BINDING CAPACITY | 321 | 250 - 450 | µg/dL |
| METHOD : TRANSFERRIN / FERENE | | | |
| % SATURATION | 23 | 13 - 45 | % |
| METHOD : CALCULATED PARAMETER | | | |

Interpretation(s)

SERUM IRON AND TIBC STUDIES-Total iron binding capacity (TIBC) measures the blood's capacity to bind iron with transferrin and thus is an indirect way of assessing transferrin level.

Taken together with serum iron and percent transferrin saturation this test is performed when there is a concern about anemia, iron deficiency or iron deficiency anemia. However, because the liver produces transferrin, alterations in liver function (such as cirrhosis, hepatitis, or liver failure) must be considered when performing this test.

Increased in:

- iron deficiency
- acute and chronic blood loss
- acute liver damage
- progesterone birth control pills

Decreased in:

- hemochromatosis
- cirrhosis of the liver
- thalassemia
- anemias of infection and chronic diseases
- nephrosis
- hyperthyroidism

The percent Transferrin saturation = Serum Iron/TIBC x 100

Unsaturated Binding Capacity (UBC)=TIBC - Serum Iron.

Limitations: Estrogens and oral contraceptives increase TIBC and Asparaginase, chloramphenicol, corticotropin, cortisone and testosterone decrease the TIBC level.

Reference:

1. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, edited by Carl A Burtis, Edward R. Ashwood, David E Bruns, 4th Edition, Elsevier publication, 2006, 563, 1314-1315.
2. Wallach's Interpretation of Diagnostic tests, 9th Edition, Ed Mary A Williamson and L Michael Snyder. Pub Lippincott Williams and Wilkins, 2011, 234-235.



Dr. Himani Sharma
Lab Head

Page 12 Of 16



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000005180288

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

Test Report Status **Final**

Results

Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

COMPLETE CARE TOTAL WITH SMART REPORT**PHYSICAL EXAMINATION, URINE**

COLOR PALE YELLOW
APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

| | | |
|--------------------|--------------|---------------|
| PH | 6.0 | 4.5 - 7.5 |
| SPECIFIC GRAVITY | 1.030 | 1.005 - 1.030 |
| PROTEIN | NOT DETECTED | NEGATIVE |
| GLUCOSE | NOT DETECTED | NEGATIVE |
| KETONES | NOT DETECTED | NOT DETECTED |
| BLOOD | NOT DETECTED | NEGATIVE |
| BILIRUBIN | NOT DETECTED | NOT DETECTED |
| UROBILINOGEN | NORMAL | NORMAL |
| NITRITE | NOT DETECTED | NOT DETECTED |
| LEUKOCYTE ESTERASE | NOT DETECTED | NOT DETECTED |

MICROSCOPIC EXAMINATION, URINE

| | | | |
|------------------|--------------|--------------|------|
| RED BLOOD CELLS | NOT DETECTED | NOT DETECTED | /HPF |
| PUS CELL (WBC'S) | 2-3 | 0-5 | /HPF |
| EPITHELIAL CELLS | NOT DETECTED | 0-5 | /HPF |
| CASTS | NOT DETECTED | | |
| CRYSTALS | NOT DETECTED | | |
| BACTERIA | NOT DETECTED | NOT DETECTED | |
| YEAST | NOT DETECTED | NOT DETECTED | |

Comments

URINE MICROSCOPIC EXAMINATION PERFORMED ON DEPOSIT AFTER CENTRIFUGATION.



Dr. Himani Sharma
Lab Head

Page 13 Of 16



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

**Patient Ref. No. 775000005180288**

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH**REF. DOCTOR : SELF**PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID:
ABHA NO :AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46**Test Report Status** **Final****Results****Biological Reference Interval** **Units****SPECIALISED CHEMISTRY - HORMONE****COMPLETE CARE TOTAL WITH SMART REPORT****THYROID PANEL, SERUM**

| | | | |
|--|--------|---------------|--------|
| T3 METHOD : CHEMILUMINESCENCE | 108.85 | 60.0 - 181.0 | ng/dL |
| T4 METHOD : CHEMILUMINESCENCE | 7.20 | 4.5 - 10.9 | µg/dL |
| TSH (ULTRASENSITIVE) METHOD : CHEMILUMINESCENCE | 2.542 | 0.550 - 4.780 | µIU/mL |

**Dr. Himani Sharma**
Lab Head

Page 14 Of 16

[View Details](#)[View Report](#)**PERFORMED AT :****Agilus Diagnostics Ltd.**Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956**Patient Ref. No. 775000005180288**

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID :
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

Test Report Status **Final**

Results

Biological Reference Interval Units

SPECIALISED CHEMISTRY - VITAMIN

COMPLETE CARE TOTAL WITH SMART REPORT

25 - HYDROXYVITAMIN D(VITAMIN D TOTAL), SERUM

25 - HYDROXYVITAMIN D

25.25 Low

Deficiency: ng/mL
< 20.0
Insufficiency:
20.0 - 30.0
Sufficiency:
30.0 - 100.0
Toxicity > 100.0

METHOD : CHEMILUMINESCENCE

VITAMIN B12(CYANOCOBALAMINE), SERUM

VITAMIN B12

342.0

211.0 - 911.0

pg/mL

METHOD : CHEMILUMINESCENCE

Interpretation(s)

25 - HYDROXYVITAMIN D(VITAMIN D TOTAL), SERUM-Test description

Vitamin D has anti-inflammatory and immune-modulating properties and it works towards the bones, teeth, intestines, immune system, pancreas, muscles and brain. It helps to maintain normal calcium and phosphate levels. Vitamin D is a fat-soluble vitamin. Also called as "Sunshine Vitamin". Two main forms as Cholecalciferol (vitamin D3) which is synthesized in skin from 7-dehydrocholesterol in response to sunlight (Type B UV) exposure & Ergocalciferol (vitamin D2) present mainly in dietary sources.

Vit D25(OH)D deficiency is seen due to poor or inadequate sunlight exposure, Nutritional or dietary deficiency or fat malabsorption, Severe Hepatocellular disease, Secondary hyperparathyroidism, Hypocalcemia tetany which can cause involuntary contraction of muscles, leading to cramps and spasms, Rickets in children, Osteomalacia in adults- due to vitamin D deficiency mainly, Older adults- osteoporosis. (Increased risk of bone fractures) due to long-term effect of calcium and/or vitamin D deficiency, Other conditions that are precipitated by Vit D deficiency included increased cardiovascular risk, low immunity & chronic renal failure.

Elevated levels may be seen in patients taking supplements(hence recommended to repeat after 3 months for estimation of accurate levels), Vitamin D intoxication, sarcoidosis and malignancies containing non regulated 1-alpha hydroxylase in the lesion.

Recommendations

1.To prevent biotin interference the patient should be atleast 8 hours fasting before submitting the sample 2.25(OH)D is the analyte of choice for determination of the Vitamin D status as it is the major storage & active form of Vitamin D and has longer half-life. 3. Kidney Disease Outcomes Quality Initiatives (KDOQI) and Kidney Disease Improving Global Outcomes (KDIGO) recommend activated vitamin D testing for CKD patients.

Note-Our Vitamin D assays is standardized to be in alignment with the ID-LC/MS/MS 25(OH)vitamin D Reference Method Procedure (RMP), the reference procedure for the Vitamin D Standardization Program (VDSP). The VDSP, a collaboration of the National Institutes of Health Office of Dietary Supplements, National Institute of Technology and Standards, Centers for Disease Control and Ghent University, is an initiative to standardize 25(OH)vitamin D measurement across methods.

Reference:

1.Wallach Interpretation of diagnostic test, 10th edition.

VITAMIN B12(CYANOCOBALAMINE), SERUM-Test description

1.Measures the amount of Vitamin B12/ Cyanocobalamin or Methyl cobalamin in blood.2. Done in Anemic conditions like Megaloblastic anemia, pernicious anemia, dietary folate deficiencies,3.Workup of neuropathies especially due to diabetes.4.Nerve health and it is monitored in treatment of nerve damage.5.Important vitamin for women of childbearing age and for older people.

1.Part of water-soluble B complex of vitamins. 2. It is essential in DNA synthesis, hematopoiesis & CNS integrity.3.Source for B12 is dietary foods like milk, yoghurt, eggs, meat, fortified cereals, bread. 4.Absorption depends on the HCl secreted by the stomach and occurs in intestines. 5. It is part of enterohepatic circulation, hence excreted in feces(approx. 0.1% per day)

Test interpretation

Higher than normal levels are in patients on Vitamin supplements or patients with COPD, CRF, Diabetes, Liver cell damage, Obesity, Polycythemia.

Decreased levels seen in

Inflammatory bowel disease, Pernicious anemia - genetic deficiency of intrinsic factor - necessary for Vit B12 absorption, Strict vegetarians lead to sub-clinical B12 deficiency- high among elderly patients, Malabsorption due to gastrectomy, smoking, pregnancy, multiple myeloma & hemodialysis, Alcohol & drugs like amino salicylic acid, anticonvulsants, cholestyramine, cimetidine, Hyperthyroidism (High levels of thyroid), Seen in mothers of children with (NTD) Neural tube defects- hence fortification and



Dr. Himani Sharma
Lab Head



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote

Amritsar, 143001

Punjab, India

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956



Patient Ref. No. 775000005180288

PATIENT NAME : PREETPAL SINGH S/O S.AMRIK SINGH

REF. DOCTOR : SELF

PREETPAL SINGH S/O S.AMRIK SINGH
AMRITSAR
Amritsar 143001

ACCESSION NO : **0202WJ007460**
PATIENT ID : PREEM19027978A
CLIENT PATIENT ID:
ABHA NO :

AGE/SEX : 44 Years Male
DRAWN : 21/10/2023 12:36:27
RECEIVED : 21/10/2023 12:39:49
REPORTED : 21/10/2023 14:56:46

Test Report Status **Final**

Results

Biological Reference Interval Units

supplements are advised in expecting mothers

Recommendations-1.To prevent biotin interference the patient should be atleast 8 hours fasting before submitting the sample. 2. Vit B12 and Folic acid evaluated together in macrocytic anemias to avoid methyl folate trap. Carmel's composite criteria for inadequate Vit B12 status: Serum vitamin B12 < 148 pmol/L, or 148-258 pmol/L and MMA > 0.30µmol/L, or tHcy > 13 nmol/L (females) and >15 nmol/L (males).

Associated Test-Holo-TC: Marker of vitamin B12 status -specificity and sensitivity better than serum vitamin B12, hence recommended in borderline and deficient cases for confirmation.

References-O'Leary F, Samman S. Vitamin B12 in health and disease. Nutrients. 2010 Mar 2(3):299-316.

****End Of Report****Please visit www.agilusdiagnostics.com for related Test Information for this accession**CONDITIONS OF LABORATORY TESTING & REPORTING**

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
2. All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.
3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form
5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII,
Mohali 160062



Dr. Himani Sharma
Lab Head

Page 16 Of 16



View Details



View Report

PERFORMED AT :**Agilus Diagnostics Ltd.**

Sco-44, Nagpal Tower-II, B-Block, Ranjit Avenue, Near M.K. Hote
Amritsar, 143001
Punjab, India
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

**Patient Ref. No. 775000005180288**